Zoersel, Belgium

Geert Verreck

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Geert Verreck: Innovator in Anticancer Pharmaceutical Formulations

Introduction

Geert Verreck is a notable inventor based in Zoersel, Belgium. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of anticancer compositions. With a total of two patents to his name, Verreck's work focuses on innovative solutions for treating androgen receptor-related diseases.

Latest Patents

Verreck's latest patents revolve around pharmaceutical formulations of ARN-509. These formulations are designed to be administered to mammals, especially humans, suffering from various forms of cancer, including prostate cancer. The patents detail the creation of solid dispersions of ARN-509, combined with a poly(meth)acrylate copolymer and HPMCAS. The formulations can be obtained through methods such as melt-extrusion and spray drying, ensuring effective delivery of the active ingredient to patients.

Career Highlights

Geert Verreck is associated with Aragon Pharmaceuticals, Inc., where he continues to advance his research in anticancer therapies. His work is pivotal in addressing the challenges faced by patients with castration-resistant prostate cancer and other related conditions. Verreck's innovative approach to pharmaceutical formulations has the potential to improve treatment outcomes for many individuals.

Collaborations

(Section skipped due to space constraints)

Conclusion

Geert Verreck's contributions to the field of pharmaceutical formulations, particularly in anticancer treatments, highlight his role as an influential inventor. His innovative work continues to pave the way for advancements in cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…